MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.

NEUTRAL Impact: 1/10 DEFA14A
Horizon immediate Filed Apr 28, 2026 Processed 1mo ago SEC 0001823239-26-000016
Proxy solicitation materials
Latest settled — T+20d
MRVI ▲ +22.75% at T+20d
NEUTRAL call ✓ call won +22.75% · α vs SPY +17.30% · entry $3.56 → $4.37
Next anchor: T+60d in 6w
Last close $5.04 (close Jun 8) · +41.57% from $3.56 entry
Entry anchored
Apr 28, 2026
via day open
T+1d
-2.25%
call -2.25% · α -2.24%
$3.48
settled 6w ago
T+5d
+8.15%
call +8.15% · α +6.45%
$3.85
settled 5w ago
T+20d
+22.75%
call +22.75% · α +17.30%
$4.37
settled 14d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Maravai LifeSciences Holdings, Inc. filed a DEFA14A to add Inline XBRL tagging to its definitive proxy statement for the 2026 Annual Meeting of Shareholders, correcting an inadvertent omission. The proxy statement covers the election of three Class III directors (Bernd Brust, Gregory T. Lucier, Luke Marker), ratification of Deloitte & Touche LLP as auditor, and an advisory say-on-pay vote. The filing is purely administrative and contains no new material information.

Actionable Insight

No trading action warranted. This is a purely technical correction to add XBRL tagging. Monitor the actual Annual Meeting on May 26, 2026, for voting outcomes, but no market-moving information is expected from this filing.

Key Facts

  • DEFA14A filed solely to add Inline XBRL tagging omitted from original proxy statement
  • No modifications or updates to any disclosures in the original proxy statement
  • Annual Meeting scheduled for May 26, 2026, at 2:30 p.m. Pacific Time, virtual-only format
  • Record date for voting is March 27, 2026
  • Proposals include election of three Class III directors, ratification of Deloitte & Touche LLP, and advisory say-on-pay vote
  • GTCR controls majority of outstanding common stock and has director nomination rights

Financial Impact

No financial impact — filing is administrative correction only

Risk Factors

  • No material risks identified from this administrative filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
59% bullish (17 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001823239-26-000016
Document: 0001823239-26-000016-index-headers.html0001823239-26-000016
Document: 0001823239-26-000016-index.html0001823239-26-000016
Document: 0001823239-26-000016.txt0001823239-26-000016
3 reports for MRVI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MRVI — sortable, filterable
Type Now
Jun 3, 2026
6d ago
8-K
BULLISH ★ 6/10
$4.84 $4.99▲ +3.10%▲ +2.70%$5.04 (+4.13%)
Apr 28, 2026
6w ago
DEFA14A
NEUTRAL ★ 1/10
$3.56 $3.48▼ −2.25%▼ −2.24%$5.04 (+41.57%)
Feb 25, 2026
15w ago
8-K
MIXED ★ 6/10
$3.26 $3.56▲ +9.20%▲ +9.75%$5.04 (+54.60%)
Showing 3 of 3

US Market Status

Market Closed — Opens in 6h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access